GPR120 Compound A – 50 mg

Brand:
Cayman
CAS:
1599477-75-4
Storage:
-20
UN-No:
Non-Hazardous - /

GPR120 (free fatty acid receptor 4/FFAR4) is a G protein-coupled receptor expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids. It has been linked to the ability of fatty acids to produce anti-inflammatory effects and to acutely potentiate insulin secretion. GPR120 compound A is an orally available, high-affinity agonist of GPR120 (EC50 = ~0.35 µM) that demonstrates potent selectivity over another lipid-sensing G-protein, GPR40 (FFAR1).{26948} This compound exerts anti-inflammatory effects on macrophages in vitro and improves glucose tolerance, decreases hyperinsulinemia, increases insulin sensitivity, and decreases hepatic steatosis when included at 30 mg/kg body weight in a high-fat diet fed to obese mice.{26948}  

 

Out of stock

SKU: - Category:

Description

An orally available, selective agonist of GPR120 (EC50 = ~0.35 µM); exerts anti-inflammatory effects on macrophages in vitro and improves glucose tolerance, decreases hyperinsulinemia, increases insulin sensitivity, and decreases hepatic steatosis when included at 30 mg/kg body weight in a high-fat diet fed to obese mice


Formal name: 3-[2-chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecane-9-acetic acid

Synonyms:  GPR120 cpdA

Molecular weight: 405.8

CAS: 1599477-75-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Immunology & Inflammation|Innate Immunity